Health
Bayer-Backed Boundless Bio Falls 11% After $100 Million IPO
- Cancer therapeutics maker priced IPO shares at middle of range
- Oncology firm’s backers also include ARCH Venture Partners
This article is for subscribers only.
Shares of Boundless Bio Inc., a cancer therapeutics maker that counts Bayer AG among its largest investors, fell nearly 11% after raising $100 million in a US initial public offering.
The San Diego-based company’s shares declined to $14.25 each on Thursday, below their IPO price of $16 — the midpoint of a $15 to $17 marketed range.